JP2019518798A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518798A5
JP2019518798A5 JP2019519626A JP2019519626A JP2019518798A5 JP 2019518798 A5 JP2019518798 A5 JP 2019518798A5 JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019518798 A5 JP2019518798 A5 JP 2019518798A5
Authority
JP
Japan
Prior art keywords
cdp
pharmaceutical composition
composition according
dag
choline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019519626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039545 external-priority patent/WO2018005527A1/en
Publication of JP2019518798A publication Critical patent/JP2019518798A/ja
Publication of JP2019518798A5 publication Critical patent/JP2019518798A5/ja
Pending legal-status Critical Current

Links

JP2019519626A 2016-06-27 2017-06-27 リポヌクレオチドに基づくardsの治療 Pending JP2019518798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355096P 2016-06-27 2016-06-27
US62/355,096 2016-06-27
PCT/US2017/039545 WO2018005527A1 (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Publications (2)

Publication Number Publication Date
JP2019518798A JP2019518798A (ja) 2019-07-04
JP2019518798A5 true JP2019518798A5 (https=) 2020-08-06

Family

ID=60786443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519626A Pending JP2019518798A (ja) 2016-06-27 2017-06-27 リポヌクレオチドに基づくardsの治療

Country Status (9)

Country Link
US (2) US10874684B2 (https=)
EP (2) EP4292651A3 (https=)
JP (1) JP2019518798A (https=)
KR (1) KR20190022682A (https=)
CN (1) CN109475554A (https=)
AU (1) AU2017289278A1 (https=)
CA (1) CA3029005A1 (https=)
SG (1) SG11201811595SA (https=)
WO (1) WO2018005527A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811595SA (en) * 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
US11154621B2 (en) 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD
EP4125857A4 (en) * 2020-03-31 2024-04-17 Diffusion Pharmaceuticals LLC USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA
WO2021222535A1 (en) * 2020-05-01 2021-11-04 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
US20250177541A1 (en) * 2022-03-11 2025-06-05 Arizona Board Of Regents On Behalf Of Arizona State University Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection
US20250170246A1 (en) * 2022-03-18 2025-05-29 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
EP2329826A1 (en) * 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
AU2002366210A1 (en) * 2001-11-21 2003-06-10 Danmarks Farmaceutiske Hojskole Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
CA2587883A1 (en) * 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
CN101495490B (zh) * 2005-05-23 2018-05-08 麻省理工学院 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
SG11201811595SA (en) * 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
US11154621B2 (en) * 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD
US11850283B2 (en) * 2017-06-27 2023-12-26 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma

Similar Documents

Publication Publication Date Title
JP2019518798A5 (https=)
JP7786743B2 (ja) 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2013518107A5 (https=)
EP3356355B1 (en) Compounds and combinations for the treatment of hiv
TR201906470T4 (tr) İmmünomodülatörler.
Murugan et al. COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks
US10874684B2 (en) Liponucleotide-based therapy for ARDS
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
JP2010270130A5 (https=)
JP2026027247A (ja) 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2013542196A5 (https=)
JP2009518410A5 (https=)
WO2022015198A1 (ru) Вакцина и способ защиты от коронавирусной инфекции
RU2012116226A (ru) Бронхолитическое средство на основе простагландина
JP6910043B2 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
Wang et al. Discovery and Development of VV116: A Novel Oral Nucleoside Anti‐SARS‐CoV‐2 Drug
KR20240052801A (ko) 플라비바이러스 치료를 위한 2'-클로로-2'-플루오로-n2-아미노-n6-메틸아미노 퓨린 뉴클레오티드
JP2011016804A5 (https=)
JP2020521838A5 (https=)
ZAREMBA et al. TOXICITY OF POLYHYDRATED FULLERENES WITH ANTI-INFLUENZA ACTIVITY IN BOTH IN VITRO AND IN VIVO SYSTEMS
RU2015144539A (ru) Антибактериальные соединения против лекарственно-устойчивых бактерий
CN103520171B (zh) Kadcoccitones A在制备治疗肾综合征出血热药物中的应用
WO2022232944A1 (en) Pharmaceutical compositions comprising vanadium salts
Wang et al. Anti HIV-1 agents 6. synthesis and anti-HIV-1 activity of indolyl glyoxamides
HK40003888A (en) Liponucleotide-based therapy for ards